With Ticagrelor and Crushing, Cangrelor Has Only a Niche Role - Paul Gurbel

↳ This is a section part of Moment: CRT 2017: ACS & AMI Management - STEMI 2017 Hot Topic: Multivessel Disease Treatment

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$14.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

With Ticagrelor and Crushing, Cangrelor Has Only a Niche Role - Paul Gurbel  at CRT 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$14.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Cardiologists
  • Interventional Cardiologists
  • Interventional Fellows
  • Interventional Radiologists
  • Vascular Surgeons
  • Emergency Physicians
  • Physicians with an interest in Cardiovascular Innovations

Learning Objectives

Other Components in this Moment

Overview
Case Introduction: A STEMI Patient with Multivessel Disease - Michael Lipinski
Culprit Only Versus Multivessel Intervention in STEMI: A Word of Caution - Barry Rutherford
Culprit Only Versus Multivessel Intervention in STEMI: Treat Them All! - Timothy Henry
Should Cangrelor Be Used in Most STEMI Patients? - Gregg Stone
Optimal Anticoagulation for Patients With STEMI Bivalirudin Versus Heparin: What Should Be the Standard of Care in 2017? - George Dangas
Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease? - Pieter Smits
With Ticagrelor and Crushing, Cangrelor Has Only a Niche Role - Paul Gurbel
What Should Be the Optimal Duration of DAPT in Patients With STEMI? - Dominick Angiolillo
When and How Should We Use Lytics in STEMI? - Eric Bates
Loading Simple Education